IP Library Granted Patent US 10,813,938
Granted Patent B2
US 10,813,938 · App. 15/756,213 · Granted Oct 27, 2020

Polymorphs of cocrystals of epigallocatechin gallate and caffeine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,813,938
App. No.
15/756,213
Granted
Oct 27, 2020
Kind
B2
Abstract

Described herein are cocrystals of epigallocatechin gallate (ECGC) and caffeine, compositions comprising such cocrystals, methods of making such cocrystals, and methods of improving animal or human health by treating with such cocrystals. In particular, Form I and Form II of a 1:2 (epigallocatechin gallate to caffeine) cocrystal are described.

Claims (10)

1. Form I of a cocrystal of epigallocatechin gallate and caffeine, wherein the cocrystal has an x-ray powder diffraction pattern with peaks at about 5.9°2θ and about 6.9°2θ, and wherein the molar ratio of caffeine to epigallocatechin gallate is 2 to 1.

2. The cocrystal according to claim 1 further comprising:

an x-ray powder diffraction pattern with one or more peaks at about 7.9, 10.6, 11.3, or 16.9°2θ.

3. The cocrystal according to claim 1 , wherein the cocrystal has a melting point of about 139° C.

4. Form II of a cocrystal of epigallocatechin gallate and caffeine, wherein the cocrystal has an x-ray powder diffraction pattern with two peaks between about 5.5°2θ and 5.8°2θ, and wherein the molar ratio of caffeine to epigallocatechin gallate is 2 to 1.

5. The cocrystal according to claim 4 further comprising:

an x-ray powder diffraction pattern with one or more peaks at about 12.2, 12.4, or 12.8°2θ.

6. The cocrystal according to claim 4 , wherein the cocrystal has a melting point of about 147° C.

7. A composition comprising a cocrystal according to claim 1 and an excipient.

8. A composition comprising a cocrystal according to claim 4 and an excipient.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2025
From: CURIA INDIANA, LLC
To: CURIA GLOBAL, INC.
Reel/Frame 073047/0677 →
CHANGE OF NAME Recorded May 20, 2025
From: AMRI SSCI, LLC
To: CURIA INDIANA, LLC
Reel/Frame 071298/0518 →
ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON MARCH 16, 2023, AT REEL/FRAME 063008/0046 Recorded Mar 17, 2025
From: BARCLAYS BANK PLC, AS EXISTING AGENT
To: APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT
Reel/Frame 070531/0241 →
SECURITY INTEREST Recorded Mar 16, 2023
From: CURIA INDIANA, LLC (F/K/A AMRI SSCI, LLC)
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 063008/0046 →
SECURITY INTEREST Recorded Mar 16, 2023
From: CURIA INDIANA, LLC (F/K/A AMRI SSCI, LLC)
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 063008/0185 →
SECURITY INTEREST Recorded Sep 6, 2021
From: CURIA GLOBAL, INC. (FKA ALBANY MOLECULAR RESEARCH, INC.); CURIA MASSACHUSETTS, INC. (FKA AMRI BURLINGTON, INC.); CURIA WISCONSIN, INC. (FKA CEDARBURG PHARMACEUTICALS, INC.); CURIA INDIANA, LLC (FKA AMRI SSCI, LLC); CURIA NEW MEXICO, LLC (FKA OSO BIOPHARMACEUTICALS MANUFACTURING, LLC); CURIA IP HOLDINGS, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 057423/0665 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2020
From: MEHTA, SHITAL VIRAL; TENG, JING; SELBO, JON
To: AMRI SSCI, LLC
Reel/Frame 053466/0542 →